DURVALUMAB, IN COMBINATION WITH AND FOLLOWING CHEMORADIOTHERAPY, IN LOCALLY ADVANCED CERVICAL CANCER: RESULTS FROM THE PHASE 3 INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CALLA TRIAL

COMPARATIVE EFFECTIVENESS OF HIPEC FOLLOWING INTERVAL CYTOREDUCTIVE SURGERY IN PATIENTS WITH ADVANCED-STAGE OVARIAN CANCER UNDERGOING NEOADJUVANT CHEMOTHERAPY: MULTICENTER, PROSPECTIVE, COHORT STUDY (KGOG 3042)

SEMINAL ABSTRACT PRESENTATION: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 ARIEL4 STUDY OF RUCAPARIB VS CHEMOTHERAPY IN PATIENTS WITH ADVANCED, RELAPSED OVARIAN CARCINOMA AND A DELETERIOUS BRCA1/2 MUTATION

CLINICAL BENEFIT OF MIRVETUXIMAB SORAVTANSINE IN OVARIAN CANCER PATIENTS WITH HIGH FOLATE RECEPTOR ALPHA EXPRESSION: RESULTS FROM THE SORAYA STUDY

MIRVETUXIMAB SORAVTANSINE AND BEVACIZUMAB IN FOLATE RECEPTOR ΑLPHA-POSITIVE OVARIAN CANCER: EFFICACY IN PATIENTS WITH AND WITHOUT PRIOR BEVACIZUMAB

MAINTENANCE OLAPARIB RECHALLENGE IN PATIENTS WITH OVARIAN CANCER PREVIOUSLY TREATED WITH A PARP INHIBITOR: PATIENT-REPORTED OUTCOMES FROM THE PHASE IIIB OREO/ENGOT-OV38 TRIAL

ATEZOLIZUMAB AND BEVACIZUMAB IN RECURRENT ENDOMETRIAL CANCER: A PHASE II, MULTI INSTITUTIONAL TRIAL

SEMINAL ABSTRACT PRESENTATION: OVERALL SURVIVAL BY NUMBER OF PRIOR LINES OF CHEMOTHERAPY IN PATIENTS WITH BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER RECEIVING OLAPARIB TREATMENT OR NON-PLATINUM CHEMOTHERAPY IN SOLO3

OVERALL SURVIVAL RESULTS FROM ARIEL3: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA

SEMINAL ABSTRACT PRESENTATION: OVERALL SURVIVAL (OS) AT 7-YEAR (Y) FOLLOW-UP (F/U) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER (OC) AND A BRCA MUTATION (BRCAM) WHO RECEIVED MAINTENANCE OLAPARIB IN THE SOLO1/GOG-3004 TRIAL

MIRVETUXIMAB SORAVTANSINE AND CARBOPLATIN FOR TREATMENT OF PATIENTS WITH RECURRENT FOLATE RECEPTOR ALPHA-POSITIVE PLATINUM-SENSITIVE OVARIAN CANCER: A FINAL ANALYSIS

POST-HOC ANALYSIS OF OBJECTIVE RESPONSE RATE BY MISMATCH REPAIR PROTEIN DIMER LOSS/MUTATION STATUS IN PATIENTS WITH MISMATCH REPAIR DEFICIENT ENDOMETRIAL CANCER TREATED WITH DOSTARLIMAB

UPDATED SAFETY OF LENVATINIB + PEMBROLIZUMAB VS TREATMENT OF PHYSICIAN’S CHOICE IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: STUDY 309/KEYNOTE-775

SEMINAL ABSTRACT PRESENTATION: ATHENA–MONO (GOG-3020/ENGOT-OV45): A RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL EVALUATING RUCAPARIB MONOTHERAPY VS PLACEBO AS MAINTENANCE TREATMENT FOLLOWING RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER

SEMINAL ABSTRACT PRESENTATION: FINAL OVERALL SURVIVAL (OS) RESULTS FROM THE PHASE III PAOLA-1/ENGOT-OV25 TRIAL EVALUATING MAINTENANCE OLAPARIB (OLA) PLUS BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER (AOC)